Single Fraction Radiation for Myeloid Sarcoma Is as Effective as Multi-Fraction Regimens for Tumor Regression and Control [0.03%]
单次分割放射治疗与多次分割放疗在髓系肉瘤肿瘤消退及控制方面同样有效
Eric G Nesbit,Michael K Rooney,Eric D Donnelly et al.
Eric G Nesbit et al.
Introduction/background: Myeloid sarcoma is a rare extramedullary manifestation of immature myeloid/monocyte cells. Radiotherapy (RT) yields good local control, but data on different fractionation schemes are limited. The...
Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review [0.03%]
复发难治多发性骨髓瘤新兴靶点及细胞治疗的系统评价
Laeth L George,Saarang R Deshpande,Matthew J Cortese et al.
Laeth L George et al.
Multiple myeloma is the second most common hematologic malignancy and remains incurable. Patients who fail multiple lines of therapy typically have a poor prognosis despite recent advances in myeloma treatment. Chimeric antigen receptor T (...
Survival Benefit and Efficiency of Low Dose Decitabine With CEG Regimen Compared to Decitabine Alone in the Elderly MDS - A Multicenter, Retrospective Study [0.03%]
低剂量地西他滨联合CEG方案与单用地西他滨治疗老年人MDS的生存优势及经济学评估-一项多中心回顾性研究
Jiexian Ma,Youdao Liang,Min Wu et al.
Jiexian Ma et al.
Background: Decitabine are used in the treatment of myelodysplastic syndrome (MDS), but none trials reported overall survival improvement. Methods: ...
Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy [0.03%]
新型靶向治疗在颗粒细胞浆树突状细胞肿瘤（BPDCN）的应用
Nathaniel R Wilson,Marina Konopleva,Joseph D Khoury et al.
Nathaniel R Wilson et al.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy arising from the aberrant transformation of plasmacytoid dendritic cells (pDCs) and involving skin, bone marrow, lymph nodes, and central nervous system. ...
Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell-Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab Therapy [0.03%]
4例利妥昔单抗治疗后新冠肺炎的B细胞耗竭型非霍奇金淋巴瘤患者接受康复者高免血浆及延长疗程瑞德西韦注射后的临床反应
Anna Furlan,Gabriella Forner,Ludovica Cipriani et al.
Anna Furlan et al.
•Four B cell–depleted non-Hodgkin lymphoma (NHL) patients with SARS-CoV-2 pneumonia after rituximab therapy were initially treated with a 5-day remdesivir course and steroids. After transient virologic and clinical response, they all expe...
Matteo Dragani,Stéphane de Botton
Matteo Dragani
There has been extraordinary progress in the field of targeted therapy for myeloid malignancies in the last few years, especially due to the approval of various agents that can be used as monotherapy or in combination as first-line treatmen...
Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades [0.03%]
急性髓系白血病的半个世纪：历史、研究进展和治疗变迁
Hagop M Kantarjian,Nicholas J Short,Amir T Fathi et al.
Hagop M Kantarjian et al.
With the Food and Drug Administration approval of 9 agents for different acute myeloid leukemia (AML) indications, the prognosis and management of AML is evolving rapidly. Herein, we review the important milestones in the history of AML res...
Aishwarya Ravindran,Patricia T Greipp,Nicholas Wongchaowart et al.
Aishwarya Ravindran et al.
Addition of Anti-thymocyte Globulin in Allogeneic Stem Cell Transplantation With Peripheral Stem Cells From Matched Unrelated Donors Improves Graft-Versus-Host Disease and Relapse Free Survival [0.03%]
在与受体人类白细胞抗原相配的非血缘外周血干细胞移植中，添加抗胸腺细胞免疫球蛋白可改善移植物抗宿主病和无复发生存率
M M Ali,B Grønvold,M Remberger et al.
M M Ali et al.
Anti-thymocyte globulin (ATG) is commonly used to prevent graft-versus-host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). To evaluate the impact of ATG as part of the GvHD prophylaxis in our institutio...
The Impact of Prior Salvage Treatment With Immune Checkpoint Inhibitors on Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Single-Center Experience [0.03%]
免疫检查点抑制剂作为挽救治疗对自体造血干细胞移植霍奇金淋巴瘤患者影响的单中心研究
Jiyeon Joy Park,Jenny Lin,Esther Huang et al.
Jiyeon Joy Park et al.
Introduction: The objective of the study was to assess the impact of the previous use of immune-checkpoint inhibitors (ICIs) on the clinical course of Hodgkin Lymphoma (HL) patients undergoing autologous hematopoietic ste...